Sökresultat
Call to Action: Implementation of Innovative, Global Strategies for Alzheimer’s Accurate Diagnosis
…gaps to drive towards accessible, early, and accurate diagnosis. The first-of-its-kind DAC-SP AccDx program recently launched with 8 sites from 5 countries, to adopt innovative blood biomarker tests in the diagnostic pathway. Partners are already working together through a Community of Practice to share learnings and find solutions to common challenges. Findings will be shared at future DAC events, including the Learning Laboratory and build on t…
Nytt test förutspÄr demens upp till 9 Är före klinisk diagnos
…value, based on the extent to which their effective connectivity pattern conformed to a pattern that indicates dementia or a control-like pattern. They compared these predictions with the recorded UK Biobank medical data for each patient. The findings showed that the model accurately predicted onset of dementia up to nine years before an official diagnosis was made, and with greater than 80% accuracy. In the cases where the volunteers had gone on…
Alexion presenterar nya data pÄ AAN
…och neuromyelit optica spectrum disorder (NMOSD). New findings from CHAMPION-NMOSD trial will reinforce the potential for Ultomiris to eliminate relapses and improve care in AQP4 Ab+ NMOSD. Long-term data and real-world evidence in gMG will underscore vital role of Ultomiris and Soliris in treatment landscape and show sustained patient benefit. Presentations include new long-term results from the pivotal Phase III CHAMPION-MG and CHAMPION-NMOSD t…
Novartis publicerar Fast 3 studien ASCLEPIOS som visar god effekt för ofatumumab för patienter med RRMS
…ple Sclerosis International Federation. Atlas of MS 2013-Mapping Multiple Sclerosis Around the World. Accessed July 10, 2020. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf 12. National MS Society. Types of MS. Accessed May 20, 2020. https://www.nationalmssociety.org/What-is-MS/Types-of-MS …
Crenezumab stoppade eller bromsade inte kognitiv försÀmring hos patienter med en specifik gen som orsakar tidig Alzheimer
…AD trial (NCT01998841) was a prospective, randomised, double-blind, placebo-controlled, parallel-group label enabling Phase II study of the efficacy of crenezumab versus placebo in cognitively unimpaired individuals who have no clinical symptoms of Alzheimer’s disease and carry the PSEN1 E280A autosomal dominant mutation. Participants who are mutation carriers were randomised in a 1:1 ratio to receive either crenezumab or placebo for at least 260…